Market Overview

PharmaCyte Biotech Successfully Completes Another Study on the Encapsulated Cells Used in Its Pancreatic Cancer Therapy

Share:

PharmaCyte
Biotech, Inc.
(OTCQB:PMCB), a clinical stage biotechnology company
focused on developing targeted cellular therapies for cancer and
diabetes using its signature live-cell
encapsulation technology, Cell-in-a-Box®,
today announced
that it has successfully completed a study on the stability after "hand
thawing" syringes of the Cell-in-a-Box® encapsulated cells
that will be used, in combination with low doses of the cancer prodrug
ifosfamide, for the treatment of locally advanced, non-metastatic,
inoperable pancreatic cancer (LAPC). The data obtained from this "hand
thawing" study is required by the U.S. Food and Drug Administration
(FDA).

The filing of an Investigational New Drug Application (IND) requires
that the clinical product, as well as the product's use, should be well
characterised. PharmaCyte's Cell-in-a-Box® is a cutting edge
Advanced Therapy Medicinal Product (ATMP). Therefore, numerous studies
are needed since such a product has never been tested before in the
United States. The laboratory scale "thawing" study previously conducted
(http://pharmacyte.com/pharmacyte-announces-successful-completion-6-month-stability-study-encapsulated-cells-clinical-trial/)
determined how long the once-frozen Cell-in-a-Box®
encapsulated cells are still fit for use after thawing, as would occur
in a clinical setting before the Cell-in-a-Box® capsules are
implanted into a patient with LAPC. That study defined one of the
important parameters for the upcoming planned clinical trial for LAPC.

At individual study sites, the frozen cells in the Cell-in-a-Box®
capsules within syringes will be hand-thawed and then kept at room
temperature until they are implanted into a patient with LAPC. The
results of the "hand thawing" study announced today show that the
viability of the cells remains essentially the same for at least 30
minutes at room temperature. This serves to define the time that the
interventional radiologist has to implant the Cell-in-a-Box®
capsules after thawing to ensure cellular viability within the patient.

PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, explained the
significance of the study saying, "This is yet another important study
that PharmaCyte has completed to comply with the FDA's requirements for
our planned, upcoming clinical trial in LAPC. The Cell-in-a-Box®
encapsulated cells are in a frozen state before they are administered to
the patient. This study was designed to determine how long after
unfreezing the Cell-in-a-Box® encapsulated cells can they be
held at room temperature before being introduced into the patient
without losing their effectiveness.

"This is important since the treatment depends on the viability of our
genetically engineered live human cells in order to produce the
cytochrome P450 enzyme for the activation of the chemotherapy prodrug
ifosfamide. The study's goal was to determine how long the cells
remained viable at room temperature after thawing; thus, mimicking how
long the clinicians and interventional radiologists will have to
administer the capsules to the patient in the hospital. The newly
completed studies show how long that Cell-in-a-Box®
encapsulated cells can be kept at room temperature for optimal activity."

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company developing
cellular therapies for cancer and diabetes based upon a proprietary
cellulose-based live cell encapsulation technology known as
"Cell-in-a-Box®." This technology will be used as a platform
upon which therapies for several types of cancer and diabetes are being
developed.

PharmaCyte's therapy for cancer involves encapsulating genetically
engineered human cells that convert an inactive chemotherapy drug into
its active or "cancer-killing" form. For pancreatic cancer, these
encapsulated cells are implanted in the blood supply to the patient's
tumor as close as possible to the site of the tumor. Once implanted, a
chemotherapy drug that is normally activated in the liver (ifosfamide)
is given intravenously at one-third the normal dose. The ifosfamide is
carried by the circulatory system to where the encapsulated cells have
been implanted. When the ifosfamide flows through pores in the capsules,
the live cells inside act as a "bio-artificial liver" and activate the
chemotherapy drug at the site of the cancer. This "targeted
chemotherapy" has proven effective and safe to use in past clinical
trials and results in no treatment related side effects.

PharmaCyte's therapy for Type 1 diabetes and insulin-dependent Type 2
diabetes involves encapsulating a human cell line that has been
genetically engineered to produce, store and release insulin in response
to the levels of blood sugar in the human body and/or beta islet cells.
The encapsulation will be done using the Cell-in-a-Box®
technology. Once the encapsulated cells are implanted in a diabetic
patient, they will function as a "bio-artificial pancreas" for purposes
of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement because of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements due to the impact of numerous risk factors,
many of which are discussed in more detail in our Annual Report on Form
10-K and our other reports filed with the Securities and Exchange
Commission.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com.
Information may also be obtained by contacting PharmaCyte's Investor
Relations Department.

View Comments and Join the Discussion!